Korro Bio dosed the first cohort in the Phase 1/2 ANCHOR trial of KRRO-121, a key milestone for its RNA-editing pipeline. The subcutaneous oligonucleotide is being tested for hyperammonemia in urea cycle disorders and hepatic encephalopathy.
published
Korro Bio dosed the first cohort in the Phase 1/2 ANCHOR trial of KRRO-121, a key milestone for its RNA-editing pipeline. The subcutaneous oligonucleotide is being tested for hyperammonemia in urea cycle disorders and hepatic encephalopathy.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.